Psoriasis Blocker
Psoriatic arthritis affects up to a third of patients with psoriasis, an autoimmune inflammation of the skin. Patients have limited mobility and functional changes that make arm movements or walking painful.
Psoriatic arthritis is difficult to treat, some of these changes are irreversible. There is an urgent need for effective treatment of joint inflammation.
Chemokines are small proteins that play an important role in the body's response to inflammation and infection. They help guide immune cells to the site of injury or injury. Chemokines act through contact with receptors, one of the specific chemokine receptors is CCR6. Researchers at the University of California, Davis evaluated the role of CCR6 and its partner, the chemokine ligand CC20 (CCL20), in inflammation associated with psoriatic arthritis and psoriasis. They tested the potential of the CCR6/CCL20 combination as an effective therapeutic target.
The researchers measured CCR6 and CCL20 levels in the joint fluid and tendon tissues of patients with psoriatic arthritis.
CCR6 is an important agent for the migration of T cells in the cutaneous form of psoriasis. A new study has shown that CCR6 plays a similar role in joint inflammation. The team found that CCL20 is also found in very high concentrations in inflamed joint fluid, making it a very attractive target for arthritis therapy.
The researchers evaluated the ability of a new engineered protein – blocked dimer CCL20 (CCL20LD) – to inhibit the function of CCR6 receptors in a mouse model of psoriatic arthritis. This protein significantly reduced inflammation of the skin and joints by disabling CCR6's ability to attract T cells.
The successful blocking of CCL20LD CCR6 function in a mouse model shows the potential for the treatment of psoriatic arthritis in humans. Additional preclinical and clinical studies are required to study its efficacy and safety.
Article Z.Shi et al. Targeting the CCR6/CCL20 axis in entheseal and cutaneous is published in the journal Inflammation, Arthritis & Rheumatology.
Aminat Adzhieva, portal "Eternal Youth" http://vechnayamolodost.ru Based on UC Davis Health: Researchers discover a potential new approach to treating psoriatic joint inflammation.